EyePoint: Phase 3 Design Creates A More Valuable Durability Story

EyePoint Pharmaceuticals approaches a binary valuation inflection with pivotal Phase III LUGANO data for DURAVYU in wet AMD due August 2026. EYPT's clinical program emphasizes repeat six-month dosing, broad patient inclusion, and direct comparison to on-label aflibercept, supporting commercial relevance. Ownership of manufacturing infrastructure and Durasert E platform applicability to both wet AMD and DME strengthens EYPT's strategic positioning. Current cash runway extends through Q4 2027, but further funding will be needed; positive trial results could significantly improve capital-raising terms.

My optimism about EyePoint ( EYPT ) rests on more than the possibility that DURAVYU will reduce injection frequency in retinal diseases. More importantly, EyePoint has designed its pivotal program around how retina specialists may use a sustained-delivery